Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
Sandra Le Quellec1,2 1Unité d’hémostase Clinique – Hôpital Cardiologique Louis Pradel – Hospices Civils de Lyon, Lyon, France; 2Service d’hématologie biologique, Groupement Hospitalier Est – Hospices Civils...
Main Author: | Le Quellec S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-02-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-evidence-and-safety-profile-of-emicizumab-for-the-management--peer-reviewed-article-DDDT |
Similar Items
-
Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report
by: Beth Boulden Warren, et al.
Published: (2021-07-01) -
Emicizumab in the treatment of hemophilia A
by: Tijanić Ivan R., et al.
Published: (2020-01-01) -
Emicizumab Associated Rhabdomyolysis in Hemophilia A
by: Joseph A. Wilson, et al.
Published: (2020-10-01) -
Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
by: Midori Shima
Published: (2020-05-01) -
Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
by: Yada K, et al.
Published: (2019-07-01)